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Abstract23
Q fever is a zoonotic disease caused by the ubiquitous pathogen Coxiella burnetii 24
responsible for acute and chronic clinical manifestations. Farm animals and pets are 25
the main reservoirs of infection, and transmission to human beings is mainly 26
accomplished through inhalation of contaminated aerosols. This illness is associated 27
with a wide clinical spectrum, from asymptomatic or mildly symptomatic 28
seroconversion to fatal disease. In humans Q fever can manifest as an acute disease 29
(mainly as a self-limited febrile illness, pneumonia, or hepatitis) or as a chronic 30
disease (mainly endocarditis), especially in patients with previous valvulopathy and to 31
a lesser extent in immunocompromised hosts and in pregnant women. In contrast in 32
animals, Q fever is in most cases, strikingly asymptomatic. The definite diagnosis of 33
Q fever is made based on a significant increase in serum antibody titers, the 34
determination of which often requires considerable time, and therefore patients must 35
be monitored for a certain period. The treatment is effective and well tolerated, but 36
must be adapted to the acute or chronic pattern with the tetracyclines to be considered 37
the mainstay of antibiotic therapy. Several actions have been proposed to prevent and 38
reduce the animal and environmental contamination. Vaccination of animals in 39
infected flocks, as well as in uninfected ones close to them, with an efficient vaccine 40
can prevent abortions and shedding of the bacteria. 41
42
43
44
45
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Introduction47
Q fever is a zoonosis caused by Coxiella burnetii, a small obligate intracellular 48
gram-negative bacterium that is prevalent throughout the world (Maurin and Raoult, 49
1999). Farm animals and pets are the main reservoirs of infection, and transmission to 50
human beings is mainly accomplished through inhalation of contaminated aerosols. 51
This illness is associated with a wide clinical spectrum, from asymptomatic or mildly 52
symptomatic seroconversion to fatal disease.53
Q fever was described in 1935 as an outbreak of febrile illness in abattoir 54
workers in Brisbane, Australia (Derrick, 1937). Derrick examined all those who were 55
affected and could not arrive at a diagnosis from the patients’ history, physical 56
examination, and a few investigations. As a result, he termed the illness “Q” for query 57
fever. Later, some workers suggested that the Q stood of Queensland, the state in 58
which the disease was first described (McDade, 1990). However, once the 59
epidemiology of the disease became known and its status as a zoonosis established, 60
this investigation lost favor. Subsequently, Burnet and Freeman (Burnet and Freeman, 61
1937) isolated a fastidious intracellular bacterium from guinea pigs that had been 62
injected with blood or urine from Derrick’s patients and named it Rickettsia burnetii. 63
This bacterium was morphologically and biochemically similar to other gram-64
negative bacteria. On the basis of cultural and biochemical characteristics, Philip 65
(Philip, 1948) classified R. burnetii in a new genus, Coxiella, named after Herald R. 66
Cox, who first isolated this microorganism in the United States. This genus contained 67
only one species, C. burnetii. Since then, it has been isolated from several mammals 68
and from ticks, and it may persist in the environment.69
During the last decade our knowledge on Q fever has greatly expanded, 70
mainly due to the identification of new clinical manifestations, the recognition of the 71
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role of host factors in the expression of acute Q fever and evolution to chronic 72
infection, and the adoption of prolonged combination antibiotic regimens for Q fever 73
endocarditis74
Bacteriology75
C. burnetii is a small, obligate intracellular Gram-negative bacterium that 76
cannot be grown in axenic medium. It is a small pleomorphic rod (0.2–0.4 μm wide, 77
0.4–1.0 μm long) with a membrane similar to that of a Gam-negative bacterium 78
(Maurin and Raoult, 1999). It replicates to high numbers within a parasitophorous 79
vacuole of eukaryotic host cells, with an estimated doubling time of 20 to 45 hours 80
(Mertens K. and Samuel, 2007). The organism may occur as a small-cell variant or 81
large-cell variant. The small-cell variant is a compact, small rod with a very electron-82
dense center of condensed nucleoid filaments. The large-cell variant is larger and less 83
electron-dense and is the metabolically active intracellular form of C. burnetii. It 84
undergoes sporogenic differentiation to produce resistant, spore-like forms, the small-85
cell variants. These are released when the cells lyse and can survive for long periods 86
in the environment. 87
C. burnetii was classified in the Rickettsiales order, the Rickettsiaceae family, 88
and the Rickettsiae tribe together with the genera Rickettsia and Rochalimaea. To date 89
based on 16S rRNA sequence analysis; the bacterium was reclassified from the order 90
Rickettsiales to Legionellales, and falls in the gamma group of Proteobacteria. Within 91
this proteobacteria group, the bacterium’s phylogenic neighbours include Legionellae 92
spp, Francisella tularensis, and Rickettsiella spp. (Raoult et al., 2005).93
C. burnetii possesses a small circular chromosome of approximately 5Mbp. Most 94
isolates harbor additionally one of four previously described plasmids of 32 to 51kb in 95
size, which carry about 2% of the genome information. Strains without a resident 96
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plasmid carry instead a 16kb plasmid-like sequence integrated in the chromosome 97
(Mallavia, 1991). The genome has a G+C content of 43 mol% and 2134 coding 98
sequences are predicted, of which 719 (33.7%) are hypothetical, with no significant 99
similarity to other genes in the database (Seshadri et al., 2003;Hoover et al., 1992).100
Moreover, many of the 83 pseudogenes that have been identified in C. burnetii101
contain single frameshifts, point mutations, or truncations which imply a recent origin 102
and indicate that genome reduction is a relatively early outgoing process (Seshadri et 103
al., 2003). Three degenerate transponsors and 20 IS elements are also identified, with 104
21 copies of a unique IS110-related isotype IS1111, five IS30 and three ISAs1 family 105
elements (Seshadri et al., 2003).   106
Epidemiology107
Q fever has been described worldwide except in New Zealand. From 1999 to 108
2004, there were 18 reported outbreaks of Q fever from 12 different countries 109
involving two to 289 people. Six outbreaks involved sheep; three involved goats; one 110
resulted from exposure to goat manure; one from exposure to ovine manure; one 111
involved exposure to wild animals; one involved exposure to cats and dogs; and in 112
two outbreaks the source was unknown (Arricau-Bouvery and Rodolakis, 2005).113
The reservoirs are extensive but only partially known and include mammals, 114
birds, and arthropods, mainly ticks. Although over 40 tick species can be naturally 115
infected with C. burnetii, they appear to not be important in the maintenance of 116
infections in livestock or humans (Maurin and Raoult, 1999). The organism does, 117
however, multiply in the gut cells of ticks and large numbers of C. burnetii are shed in 118
tick feces. Contaminated hides and wool may be a source of infection for people 119
either by direct contact or after the feces have dried and been inhaled as airborne dust 120
particles. The most commonly identified sources of human infection are farm animals 121
Page 6 of 51
Ac
ce
pte
d M
an
us
cri
pt
6
such as cattle, goats, and sheep. C. burnetii localizes to the uterus and mammary 122
glands of infected animals (Babudieri, 1959).  Pets, including cats, rabbits, and dogs, 123
have also been demonstrated to be potential sources of urban outbreaks. In North 124
America, outbreaks of Q fever have resulted from direct and indirect contact with 125
parturient cats (Marrie and Raoult, 2002). Outbreaks have also been reported 126
following exposure to infected pigeon feces (Stein and Raoult, 1999).127
Routes of transmission to humans128
Aerosols. From experimental and epidemiological evidence, there is no doubt that 129
contaminated aerosols are the major mechanism whereby C. burnetii is transmitted to 130
humans (Tiggert and Benenson, 1956;Gonder et al., 1979;Marrie et al., 1989).131
Persons in contact with farm animals can be infected by inhalation of contaminated 132
aerosols from amniotic fluid or placenta or contaminated wool but also at risk are 133
laboratory personnel who work with infected animals (Johnson, III and Kadull, 1966).134
Oral route. Mammals also shed C. burnetii in milk, and thus, consumption of raw 135
milk could be a source of infection (Maurin and Raoult, 1999). Although 136
contaminated milk can be a risk factor for Q fever infection (Marmion et al., 1956;137
Fishbein and Raoult, 1992), the evidence from experiments in which contaminated 138
milk was fed to volunteers were contradictory (Benson et al., 1963;Editorial, 139
1950;Krumbiegel and Wisniewski, 1970). Ingestion of pasteurized cheese and tobacco 140
smoking can be also risk factors for acquisition Q fever (Hatchette et al., 2000).141
Percutaneous route. Ticks transmit C. burnetii to domestic mammals but not to 142
humans (Kazar, 1996). 143
Person to person transmission. Person-to-person transmission of C. burnetii is rare. 144
Transmission of Q fever to attendants during autopsies (Harman, 1949; Gerth et al., 145
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1982) or infection from a patient to the hospital staff  (Deutch and Peterson, 1950) can 146
occur.147
Sexual transmission. A recent report describes sexual transmission (Milazzo et al., 148
2001). Sexual transmission of Q fever has been demonstrated in mice (Kruszewska 149
and Tylewska-Wierzbanowska, 1993) and viable C. burnetii has been found in bull 150
semen (Kruszewska and Tylewska-Wierzbanowska, 1997).151
Age and gender. There are several studies in which young age seems to be protective 152
against C. burnetii. In a large outbreak of Q fever in Switzerland, symptomatic 153
infection was five times more likely to occur in those over 15 years of age compared 154
with those younger than 15 (Dupuis et al., 1985). In children the sex ratio of clinical 155
cases as well as that of infections is 1:1. The change in sex ratio at puberty can be 156
explained by the protective role of 17-β-estradiol in clinical expression, which has 157
been demonstrated in mice (Leone et al., 2004)158
Transmission in animals159
Infected ticks are probably most important in maintaining the whole cycle of 160
C. burnetii (Stoker and Marmion, 1995). Ticks may play a significant role in the 161
transmission of C. burnetii among the wild vertebrates, especially in rodents, 162
lagomorphs, and wild birds (Babudieri, 1959;Lang, 1990;Marrie et al., 1989). Dogs 163
can also be infected by tick bite (Mantovani and Benazzi, 1953). Although 164
experimental transmission of C. burnetii from infected to uninfected guinea pigs via 165
tick bite has been performed with Ixodes holocyclus, Haemaphysalis bispinosa, and 166
Rhipicephalus sanguineus (Maurin and Raoult, 1999), ticks are not considered 167
essential in the natural cycle of C. burnetii infection in livestock (Babudieri, 1959).168
Ticks expel heavy loads of C. burnetii with their feces onto the skin of the animal host 169
at the time of feeding.170
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Animals which live in close contact can become infected with C. burnetii.171
Sanford et al. described abortions that occurred in goat herds that were exposed to 172
three goats from another herd that kidded prematurely during a fair (Sanford et al., 173
1994). Twenty one days after exposure abortions began and affected 20 to 46% of the 174
pregnant animals in each herd. Moreover, when cows were imported into an area of 175
endemic infection, 40% of uninfected cows became C. burnetii infected within 6 176
months (Huebner and Bell, 1951).177
Dogs may be infected by consumption of placentas or milk from infected 178
ruminants, and by the aerosol route. Anti-phase II antibody seroprevalence was found 179
ranging from 7 to 53% among wild brown rat populations in the United Kingdom and 180
the authors hypothesized that wild rats may represent a major reservoir of C. burnetii 181
from which domestic animals, especially cats, which are natural predators of these 182
animals, may become contaminated (Webster et al., 1995). 183
Pathogenicity184
A major characteristic of C. burnetii is its antigenic variation, called phase 185
variation. Organisms isolated from acutely infected animals, arthropods, or humans 186
express a wild virulent form, with smooth full length LPS named Phase I. After 187
several passages in embryonated hen eggs or cell culture, the bacterium shifts from 188
Phase I to an avirulent phase (Phase II), similar to the smooth to rough variation 189
described for many Enterobacteriaceae (Hotta et al., 2002). Phase variation is 190
probably not a single step process, as intermediate-phase or semi-rough LPS types 191
have been described (Vodkin and Williams, 1986;Amano et al., 1987). Virulent Phase 192
II bacteria express a truncated, rough LPS molecule and many differ in surface protein 193
composition, surface charge and cell density (Mertens K. and Samuel, 2007). 194
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The target cells of C. burnetii are monocytes/macrophages. Capo et al. showed 195
that virulent C. burnetii organisms survived inside human monocytes, whereas 196
avirulent bacteria were eliminated (Capo et al., 1999). In addition, they were 197
phagocytozed by host cells at markedly lower efficiency than avirulent variants. C. 198
burnetii enters monocytes/macrophages, the only known target cells, by phagocytosis 199
that differs in phase I and phase II cells. Attachment of phase I bacteria is mediated by 200
αvβ3 integrin only, whereas phase II attachment is mediated by both αvβ3 and 201
complement receptor CR3 (Capo et al., 1999). As the efficiency of CR3-mediated 202
phagocytosis depends on CR3 activation via αvβ3 integrin, the low phagocytic 203
efficiency observed with virulent C. burnetii results from the interference with 204
integrin cross-talk and a pre-treatment of monocytes with virulent bacteria prevents 205
CR3-mediated phagocytosis and CR3 activation. Virulent bacteria stimulate the 206
formation of pseudopodal extensions and transient reorganization of filamentous 207
actin, whereas avirulent agents have no effect (Meconi et al., 1998). Finally, specific 208
inhibitors of src-related kinases prevent C. burnetii stimulated reorganization of the209
cytoskeleton (Meconi et al., 2001).210
The adaptation of C. burnetii to intracellular life is linked with acidic pH of its 211
phagosome and both virulent and avirulent bacteria are found in phagosomes. Acidic 212
pH allows the entry of nutrients necessary for C. burnetii metabolism and also 213
protects bacteria from antibiotics by altering their activity (Hackstadt and Williams, 214
1981). The survival of C. burnetii in human macrophages is based on the control of 215
phagocytosis and the prevention of ultimate phagosome lysosome fusion. This is 216
based on the fact that virulent organisms are presented in phagosomes that express 217
endosomal markers such as the mannose 6-phosphate receptor, LAMP1 and proton 218
ATPase, but they do not acquire a marker such as cathepsin D. On the other hand, 219
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avirulent agents are presented in phagosomes that colocalize with cathepsin D.220
Finally, defective phagosome maturation is induced by exogenous IL-10 in monocytes 221
from patients with microbicidal competence and corrected IL-10 neutralization in 222
patients with chronic Q fever which means that phagosome maturation and C. burnetii223
killing are linked in Q fever and are controlled by cytokines (Ghigo et al., 2004).224
Toll-like receptor 4 (TLR4) has also a role in the uptake of virulent C. 225
burnetti, since it is involved in the recognition of lipopolysaccharide, and in 226
membrane ruffling induced by phase I lipopolysaccharide (Honstettre et al., 2004). 227
TLR2 is also involved in C. burnetii infection and Zamboni et al. showed that TLR2 228
is involved in TNF and interferon-γ (IFN-γ) production (Zamboni et al., 2004).229
Myeloid dendritic cells (DCs) can be infected by C. burnetii and DCs constitute a 230
protective niche for the bacteria as organisms replicate within DCs (Shannon et al., 231
2005). In contrast, avirulent bacteria which are eliminated by the host immune 232
response stimulate DC maturation and IL-12 production. Phase I bacteria escape 233
intracellular killing by inhibiting the final phagosome maturation step-cathepsin 234
fusion (Ghigo et al., 2002). IFN-γ restores this fusion step and allows intracellular 235
killing of C. burnetii by recruting the GTPase Rab7, which is involved in traffic 236
regulation (Raoult et al., 2005). Moreover IFN-γ induces the killing of C. burnetii 237
through the apoptosis of C. burnetii-infected macrophages by inducing the expression 238
of membrane tumour necrosis factor (Raoult et al., 2005).239
The control of the primary Q fever infection involves systemic cell mediated 240
immune response and granuloma formation. The granulomatous lesions have a central 241
open space and a fibrin ring, and are referred to as doughnut granulomas. Immune 242
control of C. burnetii is T-cell dependent but does not lead to C. burnetii eradication243
(Honstettre et al., 2004). C. burnetti DNA can also be found in circulating monocytes 244
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or bone marrow of people infected months or years earlier (Capo et al., 2003).245
Specific immunoglobulins are secreted following infection. IgG is mainly directed 246
against phase II antigen, whereas IgM is directed against both phase I and II cells 247
(Maurin and Raoult, 1999).248
C. burnetii infection may become chronic. Once established, chronic Q fever 249
is characterised by defective cell-mediated immunity, thus emphasizing the major role 250
of cell-mediated immunity in the protection against C. burnetii. Lymphocytes from 251
patients with Q fever endocarditis do not proliferate in response to C. burnetii antigen, 252
in contrast to lymphocytes from patients with acute Q fever (Koster et al., 1985). The 253
mechanisms of this specific unresponsiveness may include alterations in T-cell 254
subsets, but CD4 T-cell lymphopenia was observed in patie ts with Q fever 255
endocarditis (Sabatier et al., 1997). Finally, a severe inflammation is found in almost 256
every patient with Q fever endocarditis as they exhibit up-regulated levels of TNF and 257
IL-6, two inflammatory cytokines, type II TNF receptors and IL-1 receptor antagonist 258
(Mege, 2007).259
Clinical manifestations260
The main characteristic of Q fever is its clinical polymorphism, so that 261
diagnosis can only be made by systematic tests. It is likely that factors such as the 262
route of infection and the inoculum size, affect the expression of C. burnetii infection. 263
Indeed the respiratory route is associated with pneumonia and the intraperitoneal route 264
with hepatitis (Marrie et al., 1996). High inocula are associated with myocarditis 265
(Maurin and Raoult, 1999). Gender and age also affect the expression of C. burnetii266
infection. Men are symptomatic more often than women despite comparable exposure 267
and seroprevalence (Tissot-Dupont et al., 1992;Maltezou and Raoult, 2002). 268
Moreover, the prevalence of clinical cases in children significantly increases with age 269
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and symptomatic Q fever occurs more frequently in people over 15 years old 270
(Maltezou and Raoult, 2002).271
Acute Q fever272
In an epidemiological survey that took place in Marseille between 1985 and 273
1998, Q fever diagnosis was 1,070 patient with a male/female sex ratio of 2.45274
(Raoult et al., 2000). The mean age of acute Q fever patients was 45.32 ± 16.56 years 275
(range, 6-87 years). There was no statistically significant age difference according to 276
sex. Occupation was studied for 477 patients and 8% of them were farmers or 277
veterinarians, a rural existence was noted for 162 (37.9%), ingestion of farm goat 278
cheese was noted for 85/366 (23.2%), and contact with newborn or pregnant animals 279
for 142/401 (35.4%). Immunosuppression was noted for 20 patients (4.7%) (Raoult et 280
al., 2000). 281
The incubation period has been estimated to be approximately 20 days (range, 282
14 to 39 days). There is no typical form of acute Q fever and the clinical signs vary 283
greatly from patient to patient. The most frequent clinical manifestation of acute Q 284
fever is probably a self-limited febrile illness (91%) which is associated with severe 285
headaches (51%), myalgias (37%), arthralgias (27%) and cough (34%) (Tissot-286
Dupont and Raoult, 2007). The main symptoms fever, pulmonary signs, and elevated 287
liver enzyme levels can coexist. Of 323 hospitalized patients with acute Q fever in 288
France, 25% presented with the three symptoms, 40% presented with fever and 289
elevated liver enzyme levels, 17% presented with fever and pulmonary signs, and 4%290
presented with only fever, pulmonary signs, or elevated liver enzyme levels (Tissot-291
Dupont et al., 1992). Atypical pneumonia is also a major clinical presentation and 292
abnormal chest X rays can be found in 27% of the patients (Tissot-Dupont and Raoult, 293
2007). After primary infection, 60% of the patients will exhibit a symptomatic 294
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seroconversion, and only 4% of the symptomatic patients will be admitted to 295
hospitals. A chronic disease will develop in at-risk patients. 296
Prolonged fever. Prolonged fever is usually accompanied by severe headaches. The 297
fever may reach from 39 to 40°C, usually remaining elevated all day. Fever typically 298
increases to a plateau within 2 to 4 days, and then after 5 to 14 days the temperature 299
returns rapidly to normal. However, in untreated patients, fever may last from 5 to 57300
days (Derrick, 1973). The duration of fever is longer in elderly patients (Derrick, 301
1973).302
Pneumonia. Atypical pneumonia is one of the most commonly recognized forms of 303
acute Q fever. Most cases are clinically asymptomatic or mild, characterized by a 304
nonproductive cough, fever, and minimal auscultatory abnormalities, but some 305
patients present with acute respiratory distress (Raoult et al., 1990b). Pleural effusion 306
can also be present. Findings on the chest radiograph are nonspecific. The duration of 307
symptoms varies from 10 to 90 days. The mortality rate ranges from 0.5 to 1.5%, 308
depending upon the series (Tissot-Dupont et al., 1992). Pneumonia is the major 309
manifestation of acute Q fever in Nova Scotia, Canada, in the Basque country in 310
Spain, and in Switzerland, while in France, Ontario, California, and Australia,311
hepatitis is the predominant form of acute Q fever (Fournier et al., 1998).312
Hepatitis. Three major forms of hepatitis may be encountered: an infectious hepatitis-313
like form of hepatitis with hepatomegaly but seldom with jaundice, clinically 314
asymptomatic hepatitis, and prolonged fever of unknown origin with characteristic 315
granulomas on liver biopsy. Hepatitis is the most common presentation worldwide, 316
particularly in France and Australia. Alkaline phosphatase, AST, and ALT levels are 317
usually mildly elevated to two to three times the normal level (Marrie, 1988). Q fever 318
hepatitis is usually accompanied clinically by fever and less frequently by abdominal 319
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pain (especially in the right hypochondrium), anorexia, nausea, vomiting, and 320
diarrhea. Progressive jaundice and palpation of a mass in the right hypochondrium 321
have also been reported. Frequently, patients with hepatitis exhibit autoantibodies, 322
including antibodies directed to smooth muscle, anticardiolipin antibodies, 323
antiphospholipid antibodies, circulating anticoagulant, and antinuclear antibodies 324
(Tissot-Dupont and Raoult, 2007).325
Cardiac involvement. Cardiac involvement is found in 2% of the acute Q fever cases 326
and myocarditis is the leading cause of death (Fournier et al., 2001). The 327
pathophysiology of the heart damage is still not clear, although a relationship has been 328
demonstrated between the onset of a myocarditis and the inocul m size in an 329
experimental model (La Scola et al., 1997). Myocarditis may be associated with 330
pericarditis, and a pericardial effusion may be observed on chest radiographs. Clinical 331
manifestations of Q fever pericarditis are not specific and most often correspond to a 332
fever with thoracic pain. However, C. burnetii is the main cause of pericarditis in 333
southern France and a frequent one in Spain and in the United Kingdom (Tissot-334
Dupont and Raoult, 2007).335
Skin rash. Skin lesions have been found in 5 to 21% of Q fever patients in different 336
series. The Q fever rash is nonspecific and may correspond to pink macular lesions or 337
purpuric red papules of the trunk (Maurin and Raoult, 1999).338
Neurologic signs. There are 3 major neurological entities associated with Q fever: (1) 339
meningoencephalitis or encephalitis; (2) lymphocytic meningitis and (3) peripheral 340
neuropathy (Bernit et al., 2002). Patients with central nervous system involvement do 341
not demonstrate differences in predisposing conditions, but more frequently have 342
occupational exposure to goats than patients with acute Q fever but no neurological 343
involvement (Bernit et al., 2002).344
Page 15 of 51
Ac
ce
pte
d M
an
us
cri
pt
15
Chronic Q fever345
Chronic Q fever may develop many months to years after initial infection, 346
manifesting as bacterial culture-negative endocarditis in up to 75% of cases (Gami et 347
al., 2004). Chronic Q fever occurs almost exclusively in patients with predisposing 348
conditions, including those with heart valve lesions, vascular abnormalities, and 349
immunosuppression (Fenollar et al., 2001). Figure 1 shows the natural history of Q 350
fever in the absence of treatment.351
Endocarditis. The most frequent and studied preservation of chronic Q fever is 352
endocarditis (Figure 1). More than 800 cases were reported in various studies between 353
1949 and 2005 (Tissot-Dupont and Raoult, 2007). The main series were studied in the 354
United Kingdom and in Ireland (227 cases), in France (264 cases), in Spain (62 355
cases), in Israel (35 cases), in Switzerland (21 cases), in Australia (18 cases) and in 356
Canada (10 cases). Q fever endocarditis is often a severe disease associated with a 357
long diagnostic delay. Q fever represents 5% of endocarditis cases in France (Brouqui 358
and Raoult, 2006). It occurs almost exclusively in patients with a previous cardiac 359
defect or in immunocompromised patients. The aortic and mitral valves are mostly 360
involved. Q fever prosthetic valve endocarditis has been increasingly reported over 361
recent years (Maurin and Raoult, 1999). The male/female ratio is 75%, and most 362
patients are older than 40 years. The clinical presentation has changed over the last 30 363
years. With faster diagnoses, the prevalence of heart failure, hepatomegaly, 364
inflammatory syndrome, anaemia and leucopenia and abnormal liver function tests 365
have decreased significantly (Houpikian et al., 2002).366
The prognosis of chronic Q fever was dramatically improved over the course 367
of just a few years. The mortality rate was 37% in a series of 79 patients reported in 368
1987 (Raoult et al., 1987), whereas it was only 15% in more recent series of 116 369
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patients, between 1997 and 2000 (Tissot-Dupont and Raoult, 2007). Among the most 370
recently diagnosed patients the death rate was under 5% (Raoult et al., 1999) an 371
improvement that is probably related to the earlier diagnosis, the efficient treatment 372
and the better follow up (Siegman-Igra et al., 1997). 373
Other clinical manifestations of Chronic Q fever374
Vascular infection is the second most frequent presentation of Q fever. An 375
aortic aneurism can be infected by C. burnetii, leading to an intestinal fistula or a 376
spondylitis, as well as a vascular graft. The prognosis is poor in the absence of 377
treatment (Botelho-Nevers et al., 2007). 378
Other manifestations of chronic Q fever are osteoarticular infections, including 379
osteomyelitis, osteoarthritis, and aortic graft infection with contiguous spinal 380
osteomyelitis (Maurin and Raoult, 1999), chronic hepatitis in alcohol addicts (Raoult381
et al., 2000), pseudotumors of the spleen, of the lung (Lipton et al., 1987), infection of 382
a ventriculo-peritoneal drain (Lohuis et al., 1994). Chronic fatigue syndrome has also 383
been reported infrequently as a possible clinical manifestation following acute Q 384
fever. The latter may be associated with cytokine dysregulation and presents as 385
fatigue, myalgia, arthralgia, night sweats, mood changes and sleep disturbance.  386
Pregnant Women387
When a woman is infected by C. burnetii during pregnancy, the bacteria settle 388
in the uterus and in the mammary glands. The consequences are of great importance: 389
a) there is an immediate risk for the mother; b) there is an immediate risk for the fetus 390
as 100% of the fetuses abort when the infection occurs during the first trimester and 391
there is a risk of preterm delivery, or low birth-weight if infection occurs during the 392
second or third trimester; c) there is a long-term risk of chronic Q fever in the mother.393
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Few data are available on the consequences of Q fever during pregnancy. To date, 394
only 38 cases have been published, demonstrating that Q fever in pregnant women is 395
associated with high morbidity and mortality (Carcopino et al., 2007). Thus, Q fever 396
during pregnancy can result in spontaneous abortion (26%), intrauterine fetal death 397
(5.3%), premature delivery (44.7%), or intrauterine growth retardation (5.3%) 398
(Carcopino et al., 2007). Normal obstetric outcome is possible (15.8%). 399
Transplacental infection of the fetus in utero is possible, but its consequences are still 400
unknown, and its association with obstetric complications remains hypothetical 401
(Carcopino et al., 2007). In a work of our laboratory it was shown that Q fever, when 402
contracted during pregnancy, can result in abortions or neonatal deaths (9 cases, 403
38%), premature births, low birth weight (8 cases, 33%), or no abnormalities (7 cases, 404
29%) (Raoult et al., 2002). Q fever during pregnancy also has important consequences 405
for the mother, with higher risk of chronic form and spontaneous abortions of future 406
pregnancies. Although most infected pregnant women present with fever, flu-like 407
illness, severe thrombocytopenia, and atypical pneumonia have also been reported408
(Maurin and Raoult, 1999). However, Q fever in pregnant women may also be 409
asymptomatic (Marrie, 1993). Serological profiles at the time of diagnosis were 410
suggestive of acute Q fever in 14 (58.3%) of 24 pregnant women for whom serology 411
was performed and of chronic Q fever in 10 (41.7%) (Maurin and Raoult, 1999). 412
Clinical manifestations in animals413
In contrast to acute human Q fever animal infection with C. burnetii is, in 414
most cases, so strikingly asymptomatic that the term coxiellosis is considered a more 415
appropriate designation than animal Q fever (Lang, 1988). In animals, during the 416
acute phase, C. burnetii can be found in the blood, lungs, spleen, and liver whereas 417
during the chronic phase it is presented as a persistent shedding of C. burnetii in feces 418
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and urine. Most animals remain totally asymptomatic, including a lack of fever. 419
However, low birth weight animals can occur (Marrie et al., 1996). Aborted fetuses 420
usually appear normal and the abortion rates can range from 3 to 80% (Marrie, 2007). 421
Infected placentas exhibit exudates and intracotyledonary fibrous thickening. A severe 422
inflammatory reponse is noted in the myometrium of goats and metris is frequently a 423
unique manifestation of the disease in cattle (Arricau-Bouvery and Rodolakis, 2005). 424
C. burnetii can also be recovered from milk for up to 32 months. Goat shed C. 425
burnetii in feces before and after kidding and the mean duration of excretion is 20 426
days. 427
Diagnosis428
Collection and storage of specimens. C. burnetii virulence is particularly high and 429
only biosafety level 3 laboratories and experienced personnel should be allowed to 430
manipulate contaminated specimens and cultivate this microorganism from clinical 431
samples. Several human specimens are suitable for the detection of C. burnetii, but 432
their availability depends on the clinical presentation. All specimens, excluding whole 433
blood which should be kept at 4°C, should be stored at -80°C and should be 434
forwarded on dry ice to the diagnostic laboratory (Fournier et al., 1998). 435
Culture. C. burnetii isolation from biological samples is carried out on HEL cells 436
using the Shell Vial centrifugation technique (Marrero and Raoult, 1989). Cell 437
monolayers in shell vials are inoculated with 1 ml of clinical specimen and 438
centrifuged (700 x g at 20°C) for 1 h to enhance attachment and penetration of C. 439
burnetii into cells. Inoculated monolayers are incubated at 37°C in 5% CO2 for 5 to 7 440
days. C. burnetii is usually observed by microscopic examination of cell monolayers 441
after Gimenez or immunofluorescence staining442
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Immunodetection. The detection of C. burnetii in tissues is especially informative in 443
patients who are undergoing treatment for chronic Q fever. Samples can be tested 444
fresh or after formalin fixation and paraffin embedding. Immunodetection is carried 445
out using immunoperoxidase techniques or immunofluorescence with polyclonal or 446
monoclonal antibodies (Maurin and Raoult, 1999). Only this last technique can be 447
used on paraffin-embedded samples (Raoult et al., 1994). Recently, Lepidi et al.448
proposed a new method named autoimmunohistochemistry for the detection of the C. 449
burnetii endocarditis (Lepidi et al., 2006).450
Molecular biology. During the last years, several PCR based diagnostic assays were 451
developed to detect C. burnetii DNA in cell cultures and in clinical samples. These 452
assays used conventional PCR, nested PCR or real-time PCR conditions with 453
LightCycler, SYBR Green or TaqMan chemistry (Klee et al., 2006). The Light-454
Cycler Nested PCR (LCN-PCR), a rapid nested-PCR assay that uses serum as a 455
specimen and the LightCycler as a thermal cycler, targeting a multicopy 20-copy 456
htpAB-associated element sequence has been adapted for the diagnosis of both acute 457
and chronic Q fever (Fenollar and Raoult, 2007). The LCN-PCR assay may be helpful 458
in establishing an early diagnosis of chronic Q fever (Fenollar et al., 2004). Due to its 459
high sensitivity and specificity, the repetitive element, IS 11-11, is the best target gene 460
for the detection of C. burnetii in patients with active Q fever (Fenollar and Raoult, 461
2004). Recently, the complete sequences of the genome of C. burnetii became462
available, allowing a large choice of DNA targets.463
Serology. Since the clinical diagnosis is difficult, in most instances, the diagnosis of 464
Q fever relies upon serology. A variety of serological techniques are available, but the 465
indirect microimmunofluorescent antibody test has become the reference technique. 466
Immunoglobulin M antibodies reactive with phase II C. burnetii appear rapidly, reach 467
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high titers within 14 days and persist for 10 to 12 weeks (Maurin and Raoult, 1999). 468
Immunoglobulin M antibodies reactive with phase I antigens are usually at a much 469
lower titer during acute infection. Immunoglobulin G antibodies reactive with phase II 470
antigens reach peak titers about 8 weeks after the onset of symptoms, while those 471
reactive with phase I antigens develop only very slowly and remain at lower titers 472
than antibodies to phase II antigens, even after a year. In chronic Q fever, where there 473
is persistence of organisms, the IgG titers to phase I and phase II antigens may both be 474
high, and the presence of IgA antibody to phase I antigen is usually, although not 475
exclusively, associated with chronic infection. Seroconversion or a fourfold increase 476
in titer indicates acute infection. Elevated levels of IgG (>1/200) and IgM (>1/25) to 477
phase II antigens also indicate a recent infection. High titers of IgG (1/800) and/or 478
IgA (>1/50) to phase I antigen are found in chronic infections. Serology should be 479
used to follow-up patients with acute Q fever to determine if treatment was successful 480
and to enable the early diagnosis of chronic infections (Landais et al., 2007).481
Diagnosis in animals. Isolation of C. burnetii is not performed for routine diagnosis 482
in veterinary medicine. Routine diagnosis of Q fever in animals is usually established 483
by examination of fixed impressions or smears prepared from the placenta stained by 484
the Stamp, Gimenez or Machiavello methods, associated with serological tests. The 485
CF test, which is the OIE prescribed serological test, is weakly sensitive and the 486
antigen used in this test frequently fails to detect antibodies in sheep or goats 487
(Kovacova et al., 1998). The ELISA test is more sensitive than the CF test but it does 488
not allow individual identification of animals that shed C. burnetii in faeces or milk. 489
PCR kits are becoming available and provide a specific, sensitive and rapid tool for 490
the detection of C. burnetii in various clinical samples (Berri et al., 2003).491
Antimicrobial Susceptibility Testing492
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Antibiotic susceptibility testing of C. burnetii is difficult because this 493
organism is an obligate intracellular bacterium. Three models of infection have been 494
developed: animals, chick embryos and cell culture. The current method used to test 495
the antibiotic susceptibility of C. burnetii is based on cell culture models (Rolain, 496
2007).497
A number of cell lines have been used to test antibiotic activity against 498
intracellular C. burnetii, including murine macrophage-like cell lines (P388D1 and 499
J774) and a murine fibroblast cell line (L929) (Akporiaye et al., 1983;Baca et al., 500
1981;Baca et al., 1985;Burton et al., 1978;Roman et al., 1986). Yeaman et al. 501
described an acute C. burnetii infection model in acutely infected L929 cells (Yeaman502
et al., 1989). Bacteriostatic activity was demonstrated against C. burnetii Nine Mile 503
and Priscilla isolates with doxycycline (10 mg/ml), rifampin (1 mg/ml), and ofloxacin 504
(5 mg/ml). Moreover, they used chronically infected L929 cells to test the bactericidal 505
activity of antibiotics against C. burnetii (Yeaman et al., 1987). They found that the 506
percentage of infected cells was not reduced by tetracycline, erythromycin, or 507
sulfamethoxazole at concentrations up to 10 mg/ml and was only slightly reduced by 508
chloramphenicol, doxycycline, and trimethoprim, suggesting that these drugs were not 509
bactericidal. In contrast, the quinolone compounds and rifampin reduced the 510
percentage of infected cells from 100% to 2, 2, 7, and 4%, respectively, after 10 days 511
of continuous culture treatment. Torres and Raoult have developed a Shell-Vial assay 512
with human embryonic lung cells (HEL) for assessment of the bacteriostatic effect of 513
antibiotics (Torres and Raoult, 1993). By this technique, amikacin and amoxicillin 514
were not effective against C. burnetii, ceftriaxone and fucidic acid were inconsistently 515
active (Torres and Raoult, 1993), whereas cotrimoxazole, rifampin, doxycycline, 516
clarithromycin and quinolones were bacteriostatic (Rolain et al., 2005b;Maurin and 517
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Raoult, 1993). Raoult et al., using P288D1 and L929 cells, showed that pefloxacin, 518
rifampin and doxycycline (Raoult et al., 1990a) as well as clarithromycin were 519
bacteriostatic against C. burnetii (Maurin and Raoult, 1993). Moreover, Maurin et al. 520
demonstrated that the addition of a lysosomotropic alkalinizing agent, chloroquine, to 521
antibiotics improved the activities of doxycycline and pefloxacin which then became 522
bactericidal (Maurin et al., 1992). That result has been corroborated by the 523
demonstration of in vivo efficacy for the combination of doxycycline and 524
hydroxychloroquine (Raoult et al., 1999).525
High level resistance to fluoroquinolones due to an amino acid substitution of 526
Gly instead of Glu at position 87 of the GyrA has been reported (Musso et al., 1996). 527
Porins have been demonstrated in C. burnetii cells, but their potential role in antibiotic 528
resistance associated with impermeability remains undefined (Banerjee-Bhatnagar et 529
al., 1996). Moreover, C. burnetii strains have been found to present differences in 530
susceptibility to erythromycin  (Raoult et al., 1991) and in susceptibility to 531
doxycycline, ciprofloxacin, and rifampin (Yeaman and Baca, 1990). In vitro selection532
of C. burnetii strains resistant to tetracyclines has been also performed (Brezina et al., 533
1975).534
The real-time quantitative PCR (RT-PCR) assay has also been used for the 535
determination of the antibiotic susceptibility of C. burnetii (Boulos et al., 536
2004;Brennan and Samuel, 2003). RT-PCR confirmed that MICs against doxycycline, 537
fluoroquinolone compounds and rifampicin were in the range 1 to 4 mg/L and that 538
telithromycin was the most effective macrolide compound (Boulos et al., 2004). By 539
the use of this assay, for the first time a human isolate of C. burnetii resistant to 540
doxycycline was found in a patient with Q fever endocarditis (Rolain et al., 2005a).    541
Treatment542
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The guideline recommendations for the treatment of Q fever are summarised in Table 543
2.544
Treatment of Acute Q fever. The recommended regimen for acute Q fever associates 545
doxycycline (200 mg daily for 14 days) to hydroxychloroquine, which alkalinizes the 546
phagolysosomes (Maurin and Raoult, 1999) . Fluoroquinolones are considered to be a 547
reliable alternative and have been advocated for patients with Q fever 548
meningoencephalitis, because they penetrate the cerebrospinal fluid (Maurin and 549
Raoult, 1999). Cotrimoxazole and rifampin can be used in case of allergy to 550
tetracyclines or contraindication (Tissot-Dupont and Raoult, 2007). Erythromycin and 551
other new macrolides such as clarithromycin and roxithromycin, could be considered 552
a reasonable treatment for acute C. burnetii infection (Gikas et al., 2001).553
Acute Q fever in children. In children younger than 8 years, co-trimoxazole has been 554
recommended, because of the adverse effects of tetracyclines and quinolones in this 555
age group. However, it has now been admitted that age is not a contraindication to 556
doxycycline, when the antibiotic is specific of the disease (Tissot-Dupont and Raoult, 557
2007). Moreover, in patients with prolonged fever, the addition of corticosteroids to 558
treatment might prove beneficial and interferon γ was successfully administered to a 559
3-year-old child with a prolonged fever unresponsive to appropriate treatment against 560
C. burnetti (Maltezou and Raoult, 2002). 561
Acute Q fever during pregnancy. Specific treatment using cotrimoxazole (800/160) 562
BID, until delivery, associated to folinic acid (25 mg OD) is recommended (Raoult et 563
al., 2002).  Recently, Carcopino et al. compared the incidence of obstetric and 564
maternal Q fever complications for women who received long-term cotrimoxazole 565
treatment with that for women who did not receive long-term cotrimoxazole treatment566
(Carcopino et al., 2007). They found that long-term cotrimoxazole treatment protected 567
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against maternal chronic Q fever, placental infection, obstetric complications and 568
especially of intrauterine fetal death. However, obstetric complications were observed 569
in 81.1% of pregnant women who did not receive long-term cotrimoxazole therapy. 570
After delivery, if the woman shows a chronic serology profile, she should be treated 571
as a chronic case, in order to prevent endocarditis and relapsing abortions. Breast 572
feeding is contraindicated (Raoult et al., 2002)   573
Chronic Q fever. Although the optimal duration of therapy is unknown, the current 574
recommendations for the treatment of chronic Q fever are 100 mg of doxycycline 575
orally twice daily with 600 mg of hydroxychloroquine by mouth once daily for at 576
least 18 months. Serologic testing is recommended on a regular basis during therapy, 577
and the main predictive criterion of clinical cure is a decrease of phase I IgG antibody 578
titers to <200 (Karakousis et al., 2006). In general, the antibody titers decrease slowly 579
with treatment (Raoult et al., 1999). However, the kinetics of antibody titer decrease 580
in patients treated with doxycycline may vary, suggesting that some patients should be 581
treated for >18 months to be cured (Rolain et al., 2003). Successful evolution is 582
evaluated by the decrease of antibody titers (IgG and IgA) to phase I that should reach 583
two dilutions in one year at the minimum. When available, the C. burnetii strain 584
should be cultured from blood or valves in order to evaluate the doxycycline MIC: the 585
doxycycline plasmatic level should be adjusted between 1.5 and 2 MICs (Rolain et 586
al., 2005a). Hydroxychloroquine dosing should be adapted according to plasmatic 587
levels (1±0.2 mg/L). Recently, Rolain et al. found isolates of C. burnetii resistant to 588
doxycycline (MIC:8μg/mL) from patients with Q fever endocarditis (Rolain et al., 589
2005a;Rolain et al., 2005b)590
Q fever in patients at risk of chronic evolution. Acute Q fever in any patient591
presents a risk factor for chronic evolution (vascular damage, vascular or valvular 592
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graft, aneurism) and should be treated according to the same protocol as chronic cases593
(Fenollar et al., 2001). Patients with acute Q fever should be systematically tested -594
including those patients who do not have known underlying factors- 3 and 6 months 595
after the onset of disease (Landais et al., 2007). Those with phase I IgG antibody titers 596
≥1: 800 should be investigated for possible infective endocarditis using 597
transesophageal echocardiography and PCR to allow for early detection of the disease598
Treatment in ruminants599
In ruminants, antibiotic treatment generally consist in administering two 600
injections of oxytetracycline (20 mg per kg bodyweight) during the last month of 601
gestation, although this treatment does not totally suppress the abortions and the 602
shedding of C. burnetii at lambing (Berri et al., 2007). In known infected herds, 603
segregating pregnant animals indoors, burning or burying reproductive offal, or 604
administering tetracycline (8 mg/kg/day) prophylactically in the water supply prior to 605
parturition may reduce spread of the organism.606
Prevention607
Epidemiological studies indicate Q fever as a public health problem in many 608
countries, including France, the United Kingdom, Italy, Spain, Germany, Israel, 609
Greece, and Canada (Nova Scotia). In Germany, 7.8% of 21,191 tested cattle, 1.3% of 610
1,346 tested sheep, and 2.5% of 278 tested goats had evidence of C. burnetii infection611
(Hellenbrand et al., 2001). In Cyprus, the prevalence of IgG antibodies against C. 612
burnetii phase II antigen was estimated at 48.2% for goats, 18.9% for sheep, and 24% 613
for bovines (Psaroulaki et al., 2006). In Iran goats had a significantly higher average 614
seroprevalence (65.78%) than cattle (10.75%) (Khalili and Sakhaee, 2009). In 615
Zimbabwe, serological evidence of Q fever infection was found in 39% of cattle, and 616
in 10% of goats (Kelly et al., 1993). In the USA goats had a significantly higher 617
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average seroprevalence (41.6%) than sheep (16.5%) or cattle (3.4%) (McQuiston and 618
Childs, 2002). Q fever remains primarily an occupational hazard in persons in contact 619
with domestic animals such as cattle, sheep and, less frequently, goats. Persons at risk 620
from Q fever include farmers, veterinarians, abattoir workers, those in contact with 621
dairy products, and laboratory personnel performing C. burnetii culture and more 622
importantly working with C. burnetii-infected animals.623
It is important to mention that during the last years the prevalence of chronic 624
Q fever in the USA has increased because of the Iraq war. Q fever is apparently 625
hyper-endemic in Iraq and many US soldiers serving in this area have been exposed to626
C. burnetii and diagnosed as suffering by Q fever. As Q fever may reveal more then 627
10 years after primo infection (symptomatic or not and diagnosed or not), it is 628
possible that the Iraq war veterans will be an important reservoir of potential chronic 629
Q fever cases that will increase the real prevalence of the disease.630
In common with all zoonotic diseases, control of the disease in animals will 631
influence the level of disease seen in man. Appropriate tick control strategies and 632
good hygiene practice can decrease environmental contamination. Infected fetal fluids 633
and membranes, aborted fetuses and contaminated bedding should be incinerated or 634
buried. In addition, manure must be treated with lime or calcium cyanide 0.4% before 635
spreading on fields; this must be done in the absence of wind to avoid spreading of the 636
microorganism faraway. Antibiotic treatment may be performed to reduce the number 637
of abortions and the quantity of C. burnetii shed at parturition. Although it is very 638
expensive, infected animals should be removed from herds or provided with separate 639
containment facilities in which to give birth. Workers in the animal industry should be 640
fully informed about the risk factors of acquiring Q fever and laboratories should be 641
provided with appropriate safety facilities and equipment. 642
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Three types of vaccine have been proposed for providing human protection 643
against Q fever: the attenuated live vaccine (produced and tested in Russia but 644
subsequently abandoned because of concern about its safety); chloroform– methanol 645
residue extracted vaccine or other extracted vaccines (tested in animals but not 646
humans); and the whole-cell formalin-inactivated vaccine (Q-Vax), which is 647
considered acceptably safe for humans (Chiu and Durrheim, 2007). The only 648
economic study undertaken in Australia on Q fever vaccine was performed before the 649
completion of the national vaccination program and assumed a Q-Vax efficacy of 650
98% (Chiu and Durrheim, 2007). Since Q fever in humans is often an occupational 651
hazard, vaccination should be considered primarily in exposed populations (Maurin 652
and Raoult, 1999). Moreover, vaccination should probably also be considered in 653
persons not professionally exposed but at risk for chronic Q fever, including patients 654
with cardiac valve defects, vascular aneurysms, or prostheses and 655
immunocompromised patients.656
Vaccines can prevent abortion in animals, and it is evident that a phase I vaccine must 657
be used to control the disease and to reduce environmental contamination and thus, 658
the risk of transmission to humans. The widespread application of such a vaccine in 659
cattle in Slovakia in the 1970s and 1980s significantly reduced the occurrence of Q 660
fever in that country (Kovacova and Kazar, 2002). Reducing exposure to raw milk for 661
at risk people (pregnant women, patients with cardiac pathology or immunosupressed) 662
and promoting the use of pasteurized milk and its products will also contribute to 663
lowering the prevalence of Q fever.664
665
666
667
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Table 1. Guidelines for the treatment of Q fever1001
1002
Figure legends1003
Figure1. Q fever natural history in the absence of treatment1004
Figure 2. Immunohistochemical detection of C. burnetii in a resected cardiac valve 1005
from a patient with a Q fever endocarditis, using a monoclonal antibody and 1006
hematoxylin counterstain. Note the intracellular location of the bacteria in the 1007
macrophage cytoplasm (original magnification x 400).1008
1009
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Table1
Clinical feature Patient cohort Treatment Duration Reference
Acute Q fever Adults doxycycline (100 mg/day) 14 days (Maurin and Raoult, 1999)
fluoroquinolones (200 mg three times a day or 
pefloxacin (400 mg) 
14 to 21 days (Maurin and Raoult, 1999)
rifampin (1,200 mg/day) 21 days (Raoult, 1993)
Pregnant trimethoprim (320 mg) and sulfamethoxazole 
(1600 mg )
>5 weeks (Carcopino et al., 2007)
Children doxycycline (100 mg/day) 10-14 days (Maurin and Raoult, 1999)
Chronic Q fever Adults doxycycline (100 mg/day) and
hydroxychloroquine (600mg)
>18 months (Carcopino et al., 2007)
Table 1
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children trimethoprim and sulfamethoxazole >18 months (Nourse et al., 2004)
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Figure1.1
Incubation:2-3
weeks
Primary infection
60% asymptomatic
40% symptomatic
Chronic infection
Pregnancy
abortion, chronic carriage 
Endocarditis, vascular infections 
Flu like syndrome
Hepatitis
Pneumonia
Meningo encephalitis
2
Figures 1-2
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